

AMENDMENTS TO THE CLAIMS

1. **(Currently Amended)** A process of preparing cells for cell therapy, comprising the steps of:

inducing helper[[T]] T1 cells that have a nonspecific antitumor activity from leukocytes isolated from a patient; and

imparting antigen specificity to the helper[[T]] T1 cells

wherein the step of imparting antigen specificity to the helper[[T]] T1 cells comprises transducing the helper[[T]] T1 cells with a T cell receptor gene that recognizes a cancer-associated antigen.

2. (Cancelled)

3. (Previously Presented) The process for preparing cells for cell therapy according to claim 1, wherein the T cell receptor gene that recognizes a cancer-associated antigen is a MHC class I-restricted T cell receptor gene.

4. (Previously Presented) The process for preparing cells for cell therapy according to claim 1, wherein the T cell receptor gene that recognizes a cancer-associated antigen is a MHC class II-restricted T cell receptor gene.

5. (Previously Presented) The process for preparing cells for cell therapy according to any of claims 1, 3 or 4, wherein the cancer-associated antigen is selected from the group consisting of Wilms' Tumor 1, CEA, AFP, CA19-9, CA125, PSA, CA72-4, SCC, MK-1, MUC-1, p53, HER2, G250, gp-100, MAGE, BAGE, SART, MART, MYCN, BCR-ABL, TRP, LAGE, GAGE, and NY-ESO1.

6. **(Withdrawn-Currently Amended)** The process for preparing cells for cell therapy according to claim 1, wherein the step of inducing helper [[T]] T1 cells having a nonspecific antitumor activity is carried out by culturing a T cell-containing material in the presence of anti-CD3 antibody and IL-2.

7. **(Currently Amended)** The process for preparing cells for cell therapy according to any of claims 1, 3, 4 or 6, further comprising a step of purifying the helper[[T]] T1 cells to which antigen specificity has been imparted.

8. **(Currently Amended)** The process for preparing cells for cell therapy according to claim 7, wherein the step of purifying the helper[[T]] T1 cells to which antigen specificity has been imparted is carried out by using antibody-bearing magnetic beads.

9. **(Currently Amended)** A process of preparing cells for cell therapy, comprising the steps of:

inducing helper [[T 1]] T1 cells and cytotoxic [[T 1]] T1 cells that have a nonspecific antitumor activity from leukocytes isolated from a patient; and

imparting antigen specificity to the helper [[T 1]] T1 cells and cytotoxic [[T 1]] T1 cells wherein the step of imparting antigen specificity to the helper [[T 1]] T1 cells and cytotoxic [[T 1]] T1 cells comprises transducing the helper [[T 1]] T1 cells and the cytotoxic [[T 1]] T1 cells with a T cell receptor gene that recognizes a cancer-associated antigen.

10. (Cancelled)

11. (Previously Presented) The process for preparing cells for cell therapy according to claim 9, wherein the T cell receptor gene that recognizes a cancer-associated antigen is a MHC class I-restricted T cell receptor gene.

12. (Previously Presented) The process for preparing cells for cell therapy according to claim 9, wherein the T cell receptor gene that recognizes a cancer-associated antigen is a MHC class II-restricted T cell receptor gene.

13. (Previously Presented) The process for preparing cells for cell therapy according to any of claims 9, 11 or 12, wherein the cancer-associated antigen is selected from the group consisting of Wilms' Tumor 1, CEA, AFP, CA19-9, CA125, PSA, CA72-4, SCC, MK-1, MUC-

1, p53, HER2, G250, gp-100, MAGE, BAGE, SART, MART, MYCN, BCR-ABL, TRP, LAGE, GAGE, and NY-ESO1.

14. **(Withdrawn-Currently Amended)** The process for preparing cells for cell therapy according to claim 9, wherein the step of inducing helper [[T 1]] T1 cells and cytotoxic [[T 1]] T1 cells having a nonspecific antitumor activity is carried out by culturing a T cell-containing material in the presence of anti-CD3 antibody, IL-2, and IL-12.

15. **(Currently Amended)** The process for preparing cells for cell therapy according to any of claims 9, 11, 12 or 14, further comprising a step of separating the helper [[T 1]] T1 cells and cytotoxic [[T 1]] T1 cells to which antigen specificity has been imparted.

16. **(Currently Amended)** The process for preparing cells for cell therapy according to claim 15, wherein the process of separating the helper [[T 1]] T1 cells and cytotoxic [[T 1]] T1 cells to which antigen specificity has been imparted is carried out by using antibody-bearing magnetic beads.

17. **(Currently Amended)** The process for preparing cells for cell therapy according to claim 15, further comprising a step of mixing the separated helper [[T 1]] T1 cells and cytotoxic [[T 1]] T1 cells in any given proportion.

18. **(Withdrawn-Currently Amended)** Cells for cell therapy, that are produced by a process comprising the steps of:

inducing helper[[T]] T1 cells that have a nonspecific antitumor activity from leukocytes isolated from a patient; and

imparting antigen specificity to the helper[[T]] T1 cells, wherein the step of imparting antigen specificity to the helper[[T]] T1 cells comprises transducing the helper[[T]] T1 cells with a T cell receptor gene that recognizes a cancer-associated antigen.

19. **(Withdrawn-Currently Amended)** Cells for cell therapy, that are produced by a process comprising the steps of:

inducing helper [[T 1]] T1 cells and cytotoxic [[T 1]] T1 cells that have a nonspecific antitumor activity from leukocytes isolated from a patient; and

imparting antigen specificity to the helper [[T 1]] T1 cells and cytotoxic [[T 1]] T1 cells, wherein the step of imparting antigen specificity to the helper [[T 1]] T1 cells and cytotoxic [[T 1]] T1 cells comprises transducing the helper [[T 1]] T1 cells and the cytotoxic [[T 1]] T1 cells with a T cell receptor gene that recognizes a cancer-associated antigen.

20. **(Withdrawn, Currently Amended)** A method for preventing or treating tumor, comprising the steps of:

isolating leukocytes from a patient;

inducing from the leukocytes helper[[T]] T1 cells that have a nonspecific antitumor activity;

imparting antigen specificity to the helper[[T]] T1 cells, wherein the step of imparting antigen specificity to the helper[[T]] T1 cells comprises transducing the helper[[T]] T1 cells with a T cell receptor gene that recognizes a cancer-associated antigen; and

administering to the patient the helper [[T 1]] T1 cells to which antigen specificity has been imparted.

21. **(Withdrawn-Currently Amended)** A method for preventing or treating tumor, comprising the steps of:

isolating leukocytes from a patient;

inducing from the leukocytes helper [[T 1]] T1 cells and cytotoxic [[T 1]] T1 cells that have a nonspecific antitumor activity;

imparting antigen specificity to the helper [[T 1]] T1 cells and cytotoxic [[T 1]] T1 cells, wherein the step of imparting antigen specificity to the helper [[T 1]] T1 cells and cytotoxic [[T 1]] T1 cells comprises transducing the helper [[T 1]] T1 cells and the cytotoxic [[T 1]] T1 cells with a T cell receptor gene that recognizes a cancer-associated antigen; and

administering to the patient the helper [[T 1]] T1 cells and cytotoxic [[T 1]] T1 cells to which antigen specificity has been imparted.

22. (Previously Presented) The method of claim 1, wherein the T cell receptor gene is isolated from a tumor specific human cytotoxic T cell clone.